reference/21983592

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/21983592

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Clinical Trial, Phase II\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't\|Research Support, U.S. Gov't, P.H.S.
endingPage	1006
issn	1527-7755 0732-183X
issueIdentifier	6
pageRange	999-1006
publicationName	Journal of clinical oncology : official journal of the American Society of Clinical Oncology
startingPage	999
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_99bfdc53d2367b0d145acf58dc5fc57d
bibliographicCitation	Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15;21(6):999–1006. doi: 10.1200/jco.2003.05.068. PMID: 12637463.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c0fba58ab8bb76a001a2fe9ecbb42983 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3b96bf79d72b74d284dbcbc37c222772 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4f33045652eb01ec0a7ba7b3283ad1df http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_303fd1740729e4bbdc912e80c75da338 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7363dd671cce1a9be61dbdc403a1c72e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8f6ff38307131004ede76d9a750267ea http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5d223d7cee52b075bb96bb42d07c78b2 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_aeaecd250ed5e727b2d13b01b13e7b70 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7bb5038f5feed94088206eb2b49df144 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d080e10253052c10be54b9965bf128f6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a8e9e9b8f87e99e40cdda745ae6b5391 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_df52e6743fbcf4655c0d7b59e3794bdf http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_beb2de6b3bf42c53b5c3def48b8aca16 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3da1307c840dd3cc56b1548c14acc9a8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3a2bd6d480a40716abd03499addba0cc http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-2437-3920
date	2003-03-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://pubmed.ncbi.nlm.nih.gov/12637463 https://doi.org/10.1200/jco.2003.05.068
isPartOf	https://portal.issn.org/resource/ISSN/1527-7755 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/5023 https://portal.issn.org/resource/ISSN/0732-183X
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	Multicenter Phase II Study of Oral Bexarotene for Patients With Metastatic Breast Cancer
discusses	http://id.nlm.nih.gov/mesh/M0018586 http://id.nlm.nih.gov/mesh/M0001483 http://id.nlm.nih.gov/mesh/M0021484 http://id.nlm.nih.gov/mesh/M0026287 http://id.nlm.nih.gov/mesh/M0328117 http://id.nlm.nih.gov/mesh/M0250478 http://id.nlm.nih.gov/mesh/M0021234 http://id.nlm.nih.gov/mesh/M0021024 http://id.nlm.nih.gov/mesh/M0018613 http://id.nlm.nih.gov/mesh/M0028300
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D001943Q000188 http://id.nlm.nih.gov/mesh/D001943Q000473 http://id.nlm.nih.gov/mesh/D013764Q000627 http://id.nlm.nih.gov/mesh/D000970Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D020847Q000008 http://id.nlm.nih.gov/mesh/D013963Q000008 http://id.nlm.nih.gov/mesh/D011980Q000032 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D013963Q000097 http://id.nlm.nih.gov/mesh/D018572 http://id.nlm.nih.gov/mesh/D011960Q000032 http://id.nlm.nih.gov/mesh/D013629Q000008 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D004334 http://id.nlm.nih.gov/mesh/D001943Q000097 http://id.nlm.nih.gov/mesh/D000077610 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D018450 http://id.nlm.nih.gov/mesh/D018931Q000008 http://id.nlm.nih.gov/mesh/D013764Q000009 http://id.nlm.nih.gov/mesh/D017312Q000008 http://id.nlm.nih.gov/mesh/D016019 http://id.nlm.nih.gov/mesh/D004305 http://id.nlm.nih.gov/mesh/D000970Q000009 http://id.nlm.nih.gov/mesh/D000970Q000008 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D013764Q000008 http://id.nlm.nih.gov/mesh/D001943Q000737 http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D008875
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID82146 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2733526 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6983 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9683 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5282375 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7907 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8768 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7102 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8145

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128675752 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128713593 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129138006 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129679854

Total number of triples: 94.